Your session is about to expire
← Back to Search
Immunomodulator
Orencia (Abatacept) for Sjogren's Syndrome
Phase 2
Waitlist Available
Research Sponsored by Arthritis & Rheumatism Associates, P.C.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects diagnosed with Sjogren's Syndrome
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 weeks
Awards & highlights
Study Summary
This trial looked at how well the salivary glands work in people with Sjogren's syndrome.
Eligible Conditions
- Sjogren's Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 32 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Salivary gland changes
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Orencia (Abatacept)Active Control1 Intervention
Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
Group II: PlaceboPlacebo Group1 Intervention
Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
Find a Location
Who is running the clinical trial?
Arthritis & Rheumatism Associates, P.C.Lead Sponsor
2 Previous Clinical Trials
300 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,629 Previous Clinical Trials
4,126,516 Total Patients Enrolled
8 Trials studying Sjogren's Syndrome
1,626 Patients Enrolled for Sjogren's Syndrome
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger